Yantai Dongcheng Pharmaceutical Group Co., Ltd (SHE: 002675), a leading pharmaceutical company based in China, has announced that it has been granted clinical trial approval by the National Medical Products Administration (NMPA) for its innovative drug, 177Lu-LNC1008. This targeted radioactive in vivo therapeutic drug is designed to treat general advanced solid tumors.
177Lu-LNC1008 targets integrin alpha-v beta-3, a significant cell surface receptor that is instrumental in tumor progression. The drug’s precursor, LNC1008, has a high affinity for this receptor, making it a promising candidate for cancer therapy. Notably, there is currently no similar product available in the global market, highlighting the potential impact of this approval.- Flcube.com
